Category: Press Releases

Astrocyte Pharmaceuticals Announces Appointment of Christine Gallagher to Board of Directors

Groton, CT, December 14, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company developing novel cerebroprotective therapeutics for patients with brain injuries, announced today...

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic

Groton, CT, November 22, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced...

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004

Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...

Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury

Groton, CT, September 8, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced...

Lisa Manna Joins Astrocyte Pharmaceuticals as Vice President of Clinical Development Operations

Lisa Manna, RN, MBA Groton, CT, July 1, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative...

Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic

Astrocyte Pharmaceuticals

Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...

Astrocyte Pharmaceuticals Announces Expanded Clinical Advisory Board

Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board...

Astrocyte Pharmaceuticals Presents NHP Stroke Study at International Stroke Conference

Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study today at the International Stroke Conference in Los Angeles demonstrating...

Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board

Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory...

Astrocyte Pharmaceuticals Completes $2.3M Pre-A Financing Round

Cambridge, MA, June 6, 2018 – Astrocyte Pharmaceuticals Inc. announced today that it has completed a Pre-A financing round that raised over $2.3M.  The company is advancing several small molecule neuroprotective...

Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders